Publications
Publications from the sPARK research community. Filter by member authorship or year.
Publications matching selected filters
Clear filtersPancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of oncology 34 (11), 987-1002
Patient-reported adverse events during neoadjuvant therapy in a phase 2 borderline resectable pancreatic cancer clinical trial (Alliance A021501)
Annals of surgery 278 (4), 598
Patient-reported outcomes (PROs) and biomarkers in daNIS-2, a phase III study comparing NIS793 plus nab-paclitaxel/gemcitabine (NG) vs placebo plus NG in first-line (1L …
Journal of Clinical Oncology 41 (4_suppl), TPS767-TPS767
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048)
J Clin Oncol
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Nature 618(7963), 144–150
Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination …
Journal of Clinical Oncology 41 (16_suppl), 4140-4140
Phase II trial of maximal ablative irradiation because of encasement (MAIBE) for patients with potentially resectable locally advanced pancreatic cancer.
Journal of Clinical Oncology 41 (4_suppl), 710-710
Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance)
Cancer
Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)
J Clin Oncol
Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)
Clin Cancer Res
Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702
J Clin Oncol
Preoperative Treatment of Locally Advanced Rectal Cancer
N Engl J Med
Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
Cancer Med
PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal …
Journal of Clinical Oncology 41 (17_suppl), LBA2-LBA2
Radiation Therapy in Localized Pancreas Cancer: An Ongoing Conundrum
International Journal of Radiation Oncology, Biology, Physics 116 (4), 707-708
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (g …
Journal of Clinical Oncology 41 (16_suppl), TPS4198-TPS4198
Registration-based biomarkers for neoadjuvant treatment response of pancreatic cancer via longitudinal image registration
Journal of Medical Imaging 10 (3), 036002
Sleep and cancer recurrence and survival in patients with resected Stage III colon cancer: findings from CALGB/SWOG 80702 (Alliance)
Br J Cancer
Sleep and cancer recurrence and survival in patients with resected Stage III colon cancer: findings from CALGB/SWOG 80702 (Alliance) Clinical Studies
British journal of cancer 129 (2), 283-290
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
ESMO open 8 (3), 101567
The SHARON trial: A study of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell rescue for metastatic pancreatic cancer with an inherited BRCA mutation.
Journal of Clinical Oncology 41 (4_suppl), TPS774-TPS774
Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study
Cancers (Basel)
Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.
Journal of Clinical Oncology 41 (4_suppl), TPS782-TPS782
1298P Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation
Annals of Oncology 33, S1137
1304P Characterizing the clinico-genomic landscape and outcomes of KRAS G12C mutated pancreas cancer
Annals of Oncology 33, S1140
656 Exploratory platform trial to evaluate immunotherapy combinations with chemotherapy for the treatment of patients with previously untreated metastatic pancreatic …
Journal for ImmunoTherapy of Cancer 10 (Suppl 2)
Abstract C028: The lung pro-thrombotic niche drives cancer-associated thromboembolism and metastasis via extracellular vesicle ITGB2
Cancer Research 82 (22_Supplement), C028-C028
Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis
Journal of geriatric oncology 13 (4), 469-479
Alterations in somatic driver genes are associated with response to neoadjuvant FOLFIRINOX in patients with localized pancreatic ductal adenocarcinoma
Journal of the American College of Surgeons 235 (2), 342
Associations of inflammatory biomarkers with survival among patients with stage III colon cancer (CALGB/SWOG 80702 [Alliance])
Cancer Research 82 (12_Supplement), 682-682
Circulating KRAS variant-specific shedding and association with survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving …
Journal of Clinical Oncology 40 (16_suppl), 2548-2548
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer
Cancer
Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice
Clin Cancer Res
Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing
Annals of Oncology 33 (4), 426-433
Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Clin Cancer Res
Concurrent Germline BRCA1/2 and Mismatch Repair Mutations in Young-Onset Pancreatic and Colorectal Cancer: The Importance of Comprehensive Germline and Somatic Characterization to Inform Therapeutic Options
JCO Precis Oncol
Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer.
Journal of Clinical Oncology 40 (16_suppl), 4010-4010
Distinct KRAS Mutations are Enriched in Early-Stage Resected Pancreatic Ductal Adenocarcinoma
HPB 24, S280
Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.
Journal of Clinical Oncology 40 (16_suppl), 105-105
Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized …
JAMA oncology 8 (9), 1263-1270
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)
Endocrine-related cancer 29 (6), 335-344
Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation
ONCOLOGY RESEARCH AND TREATMENT 45 (SUPPL 3), 91-92
Extended Overall Survival Results from the POLO Study of active Maintenance Therapy with Olaparib in Patients with metastatic Pancreatic Cancer and a Germline BRCA Mutation
Oncology Research And Treatment 45 (SUPPL 2), 224-225
Feasibility and utility of synthetic control arms derived from real-world data to support clinical development.
Journal of Clinical Oncology 40 (4_suppl), 528-528
First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors.
Journal of Clinical Oncology 40 (16_suppl), TPS2701-TPS2701
FOLFIRINOX as initial treatment for localized pancreatic adenocarcinoma: a retrospective analysis by the Trans-Atlantic Pancreatic Surgery Consortium
JNCI: Journal of the National Cancer Institute 114 (5), 695-703
Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance).
Journal of Clinical Oncology 40 (16_suppl), 3553-3553
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
Cell 185 (3), 563-575. e11
Helping patients understand Pancreatic Cancer using animated pancreas patient Education with Visual formats of Learning
Pancreas 51 (6), 628-633
Homologous Recombination Deficiency in Pancreatic Cancer: Poly (ADP-ribose) Polymerase Inhibition, Checkpoint Inhibition, or a Combination of Both?
JCO Precis Oncol